Smith-Nephew

+ Evidence in focus

Publication summary

A randomised controlled trial (RCT) of medium and large full-thickness rotator cuff repairs augmented with the REGENETEN⁶ Bioinductive Implant demonstrated significantly lower re-tear rates, compared with repair alone, at 2-year follow-up

Ruiz Ibán MA, Navlet MG, Moros SL, et al. Augmentation with a bovine bioinductive collagen implant of a posterosuperior cuff repair shows lower retear rates but similar outcomes compared to no augmentation: 2-year results of a randomized controlled trial. *Arthroscopy*. Published online April 11, 2025.

Available at: Arthroscopy

Key points



Significantly lower re-tear rate in repairs augmented with the REGENETEN Implant (p=0.004)

Lower risk of re-tear with the REGENETEN



Patients with healed tendons had significantly better clinical outcomes, compared to those with re-tears ($p \le 0.015$)

Overview

- Blinded, multi-centre, RCT assessing the clinical and radiological outcomes of rotator cuff tears repaired with and without augmentation of the REGENETEN Implant
- 124 patients with medium and large (1–4cm) full-thickness posterosuperior rotator cuff tears were randomised (1:1) after suture anchor repair to receive either:
 - Arthroscopic transosseous equivalent (TOE) double-row rotator cuff repair (control group; n=57)
 - Arthroscopic TOE double-row rotator cuff repair augmented with the REGENETEN Implant (REGENETEN Implant group; n=57)

Results

At 2-year follow-up, compared with repair alone, repair augmented with the REGENETEN Implant demonstrated:

- Significantly better tendon integrity (87.72% vs 64.91%; p=0.020)
- Significantly lower re-tear rate (12.3% vs 35.1%; p=0.004; Figure)
- A 65% lower relative risk (RR) of re-tear (RR=0.35; 95% confidence interval [CI]: 0.161–0.762; Figure)
 - The number of patients needed to treat with the REGENETEN Implant to avoid a re-tear was 4.4 (95% CI: 2.6–12.9)
- No difference in PROMs between the REGENETEN Implant and control group
 - Post-hoc analysis found patients with healed tendons (n=87) presented significantly better clinical outcomes, compared to those with re-tears (n=25)
 - Significantly higher ASES score (84.4 vs 71.7; p=0.015)
 - Significantly higher CMS score (80.2 vs 66.2; p=0.007)
- No additional complications or reinterventions

- At 2-year follow-up, data were available for 114 patients
- There were no differences in pre-operative patient
 characteristics between groups
- Primary outcome was tendon integrity assessed on MRI using the Sugaya classification (grades ≤3 healed; ≥4 re-tears)
- Secondary outcomes were MRI characteristics, re-tear rate and patient-reported outcome measures (PROMs) including American Shoulder and Elbow Society (ASES) score and Constant-Murley score (CMS)
 - Post-hoc analysis of patients with healed tendons versus re-tears



Figure. Re-tear rate (%) and risk of re-tear at 2-years post-operatively

Conclusions

In a randomised controlled trial, the repair of full-thickness rotator cuff tears augmented with the REGENETEN Bioinductive Implant demonstrated significantly lower re-tear rates and significantly lower risk of re-tear compared with repair alone at 2-year follow-up.Patients with healed tendons presented significantly better clinical outcomes compared to those with re-tears.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Smith & Nephew, Inc. 1450 Brooks Road, Memphis, TN 38116, USA. 46931-en V1 03/25. Published March 2025. ©2025 Smith+Nephew. ≬Trademark of Smith+Nephew. All Trademarks acknowledged. Developed by Evidence Communications, Global Clinical & Medical Affairs www.smith-nephew.com